Literature DB >> 27011049

Immune evasion pathways and the design of dendritic cell-based cancer vaccines.

Brent A Hanks1.   

Abstract

Emerging data is suggesting that the process of dendritic cell (DC) tolerization is an important step in tumorigenesis. Our understanding of the networks within the tumor microenvironment that functionally tolerize DC function is evolving while methods for genetically manipulating DC populations in situ continue to develop. A more intimate understanding of the paracrine signaling pathways which mediate immune evasion by subverting DC function promises to provide novel strategies for improving the clinical efficacy of DC-based cancer vaccines. This will likely require a better understanding of both the antigen expression profile and the immune evasion network of the tumor and its associated stromal tissues.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27011049      PMCID: PMC4934601     

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  64 in total

1.  Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response.

Authors:  Gentao Liu; Hiushan Ng; Yasuharu Akasaki; Xiangpeng Yuan; Moneeb Ehtesham; Dong Yin; Keith L Black; John S Yu
Journal:  Eur J Immunol       Date:  2004-06       Impact factor: 5.532

Review 2.  Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.

Authors:  Paul J Tacken; I Jolanda M de Vries; Ruurd Torensma; Carl G Figdor
Journal:  Nat Rev Immunol       Date:  2007-10       Impact factor: 53.106

3.  A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation.

Authors:  Xiufen Zheng; Costin Vladau; Xusheng Zhang; Motohiko Suzuki; Thomas E Ichim; Zhu-Xu Zhang; Mu Li; Ewa Carrier; Bertha Garcia; Anthony M Jevnikar; Wei-Ping Min
Journal:  Blood       Date:  2009-01-22       Impact factor: 22.113

4.  Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model.

Authors:  Xiufen Zheng; James Koropatnick; Di Chen; Thomas Velenosi; Hong Ling; Xusheng Zhang; Nan Jiang; Benjamin Navarro; Thomas E Ichim; Bradley Urquhart; Weiping Min
Journal:  Int J Cancer       Date:  2012-07-20       Impact factor: 7.396

Review 5.  Fatty acid import into mitochondria.

Authors:  J Kerner; C Hoppel
Journal:  Biochim Biophys Acta       Date:  2000-06-26

Review 6.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  TGF-beta signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis.

Authors:  Yasmina Laouar; Terrence Town; David Jeng; Elise Tran; Yisong Wan; Vijay K Kuchroo; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-31       Impact factor: 11.205

Review 8.  Designing vaccines based on biology of human dendritic cell subsets.

Authors:  Karolina Palucka; Jacques Banchereau; Ira Mellman
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

9.  The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

Authors:  Takuya Osada; Gabriel Chong; Robert Tansik; Timothy Hong; Neil Spector; Rakesh Kumar; Herbert I Hurwitz; Inderjit Dev; Andrew B Nixon; H Kim Lyerly; Timothy Clay; Michael A Morse
Journal:  Cancer Immunol Immunother       Date:  2008-01-10       Impact factor: 6.968

10.  Modulation of dendritic cell maturation and function with mono- and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase.

Authors:  Gro F Flatekval; Mouldy Sioud
Journal:  Immunology       Date:  2009-03-23       Impact factor: 7.397

View more
  1 in total

1.  Molecular genetics and targeted therapy of WNT-related human diseases (Review).

Authors:  Masuko Katoh; Masaru Katoh
Journal:  Int J Mol Med       Date:  2017-07-19       Impact factor: 4.101

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.